Dalteparin

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Dalteparin and local guidelines before prescribing.

Low molecular weight heparin

Mechanism

Low molecular weight heparin enhancing antithrombin inhibition of factor Xa.

Uses

VTE prophylaxis and treatment, ACS, cancer-associated VTE, dialysis.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Bleeding, injection-site haematoma, thrombocytopenia (HIT), hyperkalaemia, osteoporosis in long-term use.

Interactions

Anticoagulants, antiplatelets and NSAIDs increase bleeding risk.

Contraindications and cautions

Active bleeding, HIT history, acute endocarditis

Monitoring

Platelets, anti-Xa in renal impairment

Pregnancy and breastfeeding

Used in pregnancy

Renal and hepatic impairment

Accumulates in renal impairment

Overdose and reversal

Protamine partially reverses

Special advice

Dose by weight; reduce or monitor anti-Xa in renal impairment; check platelet count on prolonged treatment.

More from the textbook: uses, cautions and other points
Where it is discussed in the book